R. Rulach

ORCID: 0000-0002-3148-0647
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Treatments and Mutations
  • Head and Neck Cancer Studies
  • Advanced Radiotherapy Techniques
  • Cancer Treatment and Pharmacology
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Glioma Diagnosis and Treatment
  • Management of metastatic bone disease
  • Cancer Immunotherapy and Biomarkers
  • Effects of Radiation Exposure
  • Head and Neck Surgical Oncology
  • Cancer Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Microtubule and mitosis dynamics
  • Brain Metastases and Treatment
  • Medical Imaging Techniques and Applications
  • Cancer Genomics and Diagnostics
  • Advances in Oncology and Radiotherapy
  • Lung Cancer Research Studies
  • Salivary Gland Disorders and Functions
  • Brain Tumor Detection and Classification
  • Salivary Gland Tumors Diagnosis and Treatment
  • Radiation Effects in Electronics
  • Economic and Financial Impacts of Cancer

Beatson West of Scotland Cancer Centre
2014-2024

University of Glasgow
2019-2022

NHS Greater Glasgow and Clyde
2020

Patients treated with curative-intent lung radiotherapy are in the group at highest risk of severe complications and death from COVID-19. There is therefore an urgent need to reduce risks associated multiple hospital visits their anti-cancer treatment. One recommendation consider alternative dose-fractionation schedules or techniques. This would also increase service capacity for operable patients stage I-III cancer, who might be unable have surgery during pandemic.Here we identify...

10.1016/j.clon.2020.05.001 article EN other-oa Clinical Oncology 2020-05-13

Thoracic reirradiation for non-small cell lung cancer with curative intent is potentially associated severe toxicity. There are limited prospective data on the best method to deliver this treatment. We sought develop expert consensus guidance safe practice of treating radiation therapy in setting prior thoracic irradiation.Twenty-one oncologists were invited participate an international Delphi process. Guideline statements developed and refined during 4 rounds definition reirradiation,...

10.1016/j.adro.2021.100653 article EN cc-by Advances in Radiation Oncology 2021-01-20

To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) first year use outside a clinical trial.Patients West Scotland Cancer Network with newly diagnosed mPC were identified from regional multidisciplinary team meetings their treatment details collected electronic patient records. The rate febrile neutropenia, hospitalisations, time to progression, overall survival compared between those patients who received...

10.1111/bju.14025 article EN BJU International 2017-09-20

Introduction Pembrolizumab, an immune-checkpoint inhibitor, is approved for first-line treatment of metastatic NSCLC in patients with tumours expressing programmed death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥50%. We aimed to clarify some uncertainties regarding use immunotherapy previous autoimmune (AI) disorders and assess real-world outcomes following completion. Methods performed a retrospective case record review 82 PD-L1 at TPS ≥ 50% receiving Pembrolizumab. Survival was...

10.1177/10781552221079356 article EN Journal of Oncology Pharmacy Practice 2022-02-15

2025 Background: BAL101553 (prodrug of BAL27862) is a novel TCC that promotes tumor cell death by modulating the spindle assembly checkpoint. BAL27862 lipophilic, small molecule shown in rodents to penetrate brain (brain/plasma ratio around unity), with promising antitumor activity orthotopic preclinical GBM models as monotherapy or combination radiotherapy (RT) without temozolomide. In this ongoing study (NCT02490800, CDI-CS-002), daily oral was initially examined solid-tumor patients, an...

10.1200/jco.2019.37.15_suppl.2025 article EN Journal of Clinical Oncology 2019-05-20

Over 60% of patients treated with chemo-IMRT for head and neck cancer experience grade 3 acute side effects.Acute toxicities include fatigue, mucositis, pain, taste disturbance, reduced oral intake, dysphagia, aspiration pneumonia, requirement tube feeding hospital admissions, which can result in treatment gaps poor chemotherapy compliance.Acute are also a

10.1016/s0167-8140(19)30189-6 article EN cc-by-nc-nd Radiotherapy and Oncology 2019-03-01
Coming Soon ...